GSK stock steadies as $10.6bn Nuvalent deal turns focus to lung-cancer approvals
GSK shares traded at 1,905.5p midday Wednesday, up 0.11%, after the company agreed to buy Boston-based Nuvalent for $10.6 billion in cash. The deal gives GSK two late-stage lung cancer drugs under FDA review, with decision dates set for September and November. GSK maintained its 2026 financial guidance and said the purchase would be funded mainly with debt and cash, with no change to its expected 70p dividend.